CLDX stock reaction and recent performance

Celldex Therapeutics (CLDX) has been moving without a clear single news catalyst. This puts the focus on how the stock has behaved recently and what its fundamentals look like today.

Over the past month the share price has recorded a 3.4% decline, while the past 3 months show a 3% decline. Year to date, CLDX is down about 4%, although the 1 year total return stands at 7.9%.

At a share price of US$25.92, Celldex’s 1 day share price return of a 3.46% decline sits against a 1 year total shareholder return of 7.91%, while the 3 year total shareholder return of a 43.96% decline suggests longer term momentum has been fading.

If you are looking beyond a single biotech name, this could be a good moment to scan similar opportunities across healthcare stocks to see how other companies in the space compare.

With CLDX showing mixed returns, fast growing revenue but a heavy net loss of US$224.532 million, and trading at a wide intrinsic discount, should you view this as a fresh entry point or assume the market is already pricing in future growth?

Preferred Price-to-Book of 2.9x: Is it justified?

Celldex is currently trading on a P/B of 2.9x, which sits slightly above the US Biotechs industry average of 2.7x but below a peer group average of 5.6x.

P/B compares the market value of the company to its book value, so it can be a useful lens for early stage or unprofitable biotechs where earnings are not yet meaningful. With Celldex still loss making, this kind of balance sheet based marker often becomes a key reference point for investors assessing how much they are paying for the underlying assets and research pipeline.

The data suggests that while the stock screens as expensive against the broader US Biotechs industry on a simple P/B check, it looks cheaper than a closer peer set whose average multiple is materially higher. That split hints at a market view that Celldex sits somewhere in the middle, with the share price neither at a clear discount nor at the kind of premium often reserved for names with stronger profitability or larger revenue bases.

Result: Price-to-book of 2.9x (ABOUT RIGHT)

However, you still need to weigh clinical and regulatory uncertainty around Barzolvolimab and CDX-622, as well as the current annual net loss of US$224.532 million.

Another view on value: DCF vs P/B

While the 2.9x P/B suggests Celldex is only roughly in line with asset based peers, our DCF model presents a different perspective. On that approach, the shares at US$25.92 are trading about 69% below an estimated future cash flow value of US$83.54.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 864 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Celldex Therapeutics Narrative

If this framing does not quite match your view, or you prefer to work through the numbers yourself, you can build a personalised take in minutes. Start with Do it your way.

A great starting point for your Celldex Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop at a single stock, you risk missing opportunities that might fit your goals even better, so widen your search before you make your next move.

• Zero in on potential value gaps by scanning these 864 undervalued stocks based on cash flows that currently trade at a discount based on projected cash flows and fundamentals.
• Explore the development of machine learning, automation, and data driven platforms by checking out these 24 AI penny stocks that are shaping real world applications.
• Review opportunities in emerging digital finance by looking at these 18 cryptocurrency and blockchain stocks connected to blockchain infrastructure, payments, and related services.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.